Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Renin Angiotensin System
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Renin Angiotensin System or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Renin Angiotensin System and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
The Long-Term Impact of Renin-AngiotensinSystem (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB
Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy The effect of angiotensin II receptor blockers on right ventricular (RV) function is still unknown. Angiotensin II receptor blockers are beneficial in patients with acquired left ventricular dysfunction, and recent findings have suggested (...) a favorable effect in symptomatic patients with systemic RV dysfunction. The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot.The REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) is an investigator-initiated, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study. Adults with repaired
Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-AngiotensinSystem Functional roles of the angiotensin peptides of the renin-angiotensinsystem (RAS) cascade can be analyzed through their corresponding proteolytic regulatory enzymes aspartyl aminopeptidase (ASAP), aminopeptidase A (APA), aminopeptidase B (APB), aminopeptidase N (APN) and insulin-regulated aminopeptidase (IRAP). These enzyme activities (...) generate active or inactive angiotensin peptides that alter the ratios between their bioactive forms, regulating several important processes such as the regulation of cardiovascular functions, body water regulation, normal memory consolidation and retrieval, but also cell growth, differentiation and apoptosis or the inflammatory response. We have previously described that the treatment with hydroxytyrosol but not with oleuropein or with the mixture of both compounds led to the significant inhibition
How is the Brain Renin-AngiotensinSystem Regulated? 28559391 2018 01 29 2018 11 13 1524-4563 70 1 2017 07 Hypertension (Dallas, Tex. : 1979) Hypertension How Is the Brain Renin-AngiotensinSystem Regulated? 10-18 10.1161/HYPERTENSIONAHA.117.08550 Nakagawa Pablo P From the Department of Pharmacology, UIHC Center for Hypertension Research, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City. Sigmund Curt D CD From the Department of Pharmacology, UIHC Center (...) Angiotensin II EC 188.8.131.52 Peptidyl-Dipeptidase A EC 184.108.40.206 Renin EC 3.6.1.- Vacuolar Proton-Translocating ATPases IM Angiotensin II metabolism Angiotensinogen metabolism Animals Blood Pressure physiology Brain metabolism Humans Peptidyl-Dipeptidase A metabolism Receptors, Cell Surface metabolism Renin metabolism Renin-AngiotensinSystem physiology Vacuolar Proton-Translocating ATPases metabolism 2017 6 1 6 0 2018 1 30 6 0 2017 6 1 6 0 ppublish 28559391 HYPERTENSIONAHA.117.08550 10.1161/HYPERTENSIONAHA
Serum creatinine elevation after renin-angiotensinsystem blockade and long term cardiorenal risks: cohort study. Objective To examine long term cardiorenal outcomes associated with increased concentrations of creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.Design Population based cohort study using electronic health records from the Clinical Practice Research Datalink and Hospital Episode Statistics.Setting UK primary care, 1997-2014 (...) .Participants Patients starting treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (n=122 363).Main outcome measures Poisson regression was used to compare rates of end stage renal disease, myocardial infarction, heart failure, and death among patients with creatinine increases of 30% or more after starting treatment against those without such increases, and for each 10% increase in creatinine. Analyses were adjusted for age, sex, calendar period, socioeconomic status
The Combination of Beta Blockers and Renin-AngiotensinSystem Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study Although several studies suggest that the prognosis of hypertensive dialysis patients can be improved by using antihypertensive drug therapy, it is unknown whether the prescription of a particular class or combination of antihypertensive drugs is beneficial during hemodialysis.We performed a propensity score matching study to compare (...) the effectiveness of various classes of antihypertensive drugs on cardiovascular (CV) mortality in 2518 incident hemodialysis patients in Spain. The patients had initially received antihypertensive therapy with a renin-angiotensinsystem (RAS) blocker (728 patients), a ß-blocker (679 patients), antihypertensive drugs other than a RAS blocker or a ß-blocker (787 patients), or the combination of a ß-blocker and a RAS inhibitor (324 patients). These patients were followed for a maximum of 5 years (median: 2.21 yr
Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac (...) MD FRCP and Peter Winocour MD FRCP July 2017 Contents Introduction 3 Evidence grades for the recommendations 3 Search strategy 3 1 Hypertension management and renin-angiotensin-aldosterone system blockade in patients with type 1 diabetes 5 Recommendations 6 Audit standards 6 Areas that require further research 7 Introduction 7 Hypertension in patients with type 1 diabetes 8 Modulation of the RAAS in patients with type 1 diabetes 9 2 Hypertension management and renin-angiotensin-aldosterone system
Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensinsystem for the treatment of heart failure. The magnitude of the clinical benefits produced by inhibitors of the renin-angiotensinsystem in heart failure has been modest, possibly because of the ability of renin-angiotensin activity to escape from suppression during long-term treatment. Efforts to intensify pharmacological blockade by use of dual inhibitors that interfere (...) with the renin-angiotensinsystem at multiple sites have not yielded consistent incremental clinical benefits, but have been associated with serious adverse reactions. By contrast, potentiation of endogenous compensatory vasoactive peptides can act to enhance the survival effects of inhibitors of the renin-angiotensinsystem, as evidenced by trials that have compared angiotensin-converting enzyme inhibitors with drugs that inhibit both the renin-angiotensinsystem and neprilysin. Several endogenous
Renin-angiotensinsystem drugs Renin-angiotensinsystem drugs: dual ther Renin-angiotensinsystem drugs: dual therap apy y Key therapeutic topic Published: 15 January 2015 nice.org.uk/guidance/ktt2 pathways Options for local implementation Options for local implementation Dual therapy with an angiotensin-converting enzyme (ACE) inhibitor plus an angiotensin receptor blocker (ARB) has only a limited place in treatment, specifically in a small minority of people with heart failure. Review (...) heart failure and there was an increased risk of hyperkalaemia, hypotension, and impaired renal function. See the NICE medicines evidence commentary Efficacy and safety of dual blockade of the renin-angiotensinsystem for more information. UK Medicines Information (UKMi) has also published a medicines question and answers resource on the rationale and evidence for combining ACE inhibitors with ARBs for treating hypertension and for preventing vascular events. Dual therapy has only a limited place
Efficacy and safety of supramaximal titrated inhibition of renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy. The optimal dosing strategies for blocking the renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy (IDCM) are poorly known. We sought to determine the long-term efficacy and safety of supramaximal titration of benazepril and valsartan in patients with IDCM.480 patients with IDCM in New York Heart Association functional class II-IV
The End of Dual Therapy with Renin-Angiotensin-Aldosterone System Blockade? 24206456 2013 11 22 2018 12 02 1533-4406 369 20 2013 Nov 14 The New England journal of medicine N. Engl. J. Med. The end of dual therapy with renin-angiotensin-aldosterone system blockade? 1960-2 10.1056/NEJMe1312286 de Zeeuw Dick D From the Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. eng Editorial Comment 2013 11 09 United States N Engl (...) J Med 0255562 0028-4793 0 Angiotensin II Type 1 Receptor Blockers 0 Angiotensin-Converting Enzyme Inhibitors E7199S1YWR Lisinopril JMS50MPO89 Losartan AIM IM N Engl J Med. 2013 Nov 14;369(20):1892-903 24206457 Angiotensin II Type 1 Receptor Blockers therapeutic use Angiotensin-Converting Enzyme Inhibitors therapeutic use Diabetic Nephropathies drug therapy Female Humans Lisinopril therapeutic use Losartan therapeutic use Male 2013 11 12 6 0 2013 11 12 6 0 2013 12 16 6 0 ppublish 24206456 10.1056
Effect of dual blockade of the renin-angiotensinsystem on the progression of type 2 diabetic nephropathy: a randomized trial Blockade of the renin-angiotensinsystem with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has been shown to lessen the rate of decrease in glomerular filtration rate in patients with diabetic nephropathy.A multicenter open-label randomized controlled trial to compare the efficacy of combining the angiotensin-converting enzyme inhibitor (...) lisinopril and the angiotensin II receptor blocker irbesartan with that of each drug in monotherapy (at both high and equipotent doses) in slowing the progression of type 2 diabetic nephropathy.133 patients with type 2 diabetic nephropathy (age, 66 ± 8 years; 76% men) from 17 centers in Spain.Patients were randomly assigned (1:1:2) to lisinopril (n = 35), irbesartan (n = 28), or the combination of both (n = 70).The primary composite outcome was a >50% increase in baseline serum creatinine level, end
Efficacy and safety of dual blockade of the renin-angiotensinsystem: meta-analysis of randomised trials Efficacy and safety of dual blockade of the renin-angiotensinsystem: meta-analysis of randomised trials Efficacy and safety of dual blockade of the renin-angiotensinsystem: meta-analysis of randomised trials Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH CRD summary The authors concluded that compared with monotherapy, combination blockade of the renin-angiotensinsystem had some (...) beneficial effects, but it did not reduce mortality and significantly compromised safety. Despite some limitations in the review, there were a lot of trials, and larger trials tended to find similar effects, which suggests that the authors' conclusions are likely to be reliable. Authors' objectives To compare the long-term efficacy and safety of individual versus combined blockade of the renin-angiotensinsystem, for patients with various disorders. Searching PubMed, EMBASE, and Cochrane Central Register
Effects of renin-angiotensinsystem blockades on cardiovascular outcomes in patients with diabetes mellitus: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.